Widmark burdens in 2009 cancer those receiving combination treatment. Berg N/A 5 years Locally Evaluated 2009 3.75mg HRQoL and (n=86) equiv. hormonal monthly changes in for 3 cancer those who’d months. used ADT for 5 years, adjuvant to 750mg RT. daily until Compared with NORM, or patients death scored statistically (p +3D conf. < 0.05) and RT clinically 3/12 of (effect size ≥ ADT. 0.4) lower on sexual domains, and statistically (p < 0.05) lower on physical function and vitality. Estimated free testosterone and measured serum oestradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment. Kohutek EBRT, EBRT or At least 5 T1-T3 ADT at time of Although 2016 years RT: low level (n=2011) or assessed cancer significantly data, a both or both. for higher 10 year large first 5 incidence of population + years, then cardiovascular studied. A annually. events (CE: long-term 7.5mg 19.6%; 95% CI safety item monthly 17.0-22.6%) to consider
Widmark 2009 cancer burdens in those receiving combination treatment. Berg 2009 (n=86) 3.75mg equiv. monthly for 3 months. 750mg daily until or death +3D conf. RT 3/12 of ADT. N/A 5 years Locally cancer Evaluated HRQoL and hormonal changes in those who’d used ADT for 5 years, adjuvant to RT. Compared with NORM, patients scored statistically (p < 0.05) and clinically (effect size ≥ 0.4) lower on sexual domains, and statistically (p < 0.05) lower on physical function and vitality. Estimated free testosterone and measured serum oestradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment. Kohutek 2016 (n=2011) EBRT, or both + 7.5mg monthly EBRT or or both. At least 5 years assessed for first 5 years, then annually. T1-T3 cancer ADT at time of RT: significantly higher 10 year incidence of cardiovascular events (CE: 19.6%; 95% CI 17.0-22.6%) Although low level data, a large population studied. A long-term safety item to consider
auspar-leuprorelin-180905.docx